Recent papers:

• Emerging antiviral targets for influenza A virus.
  
  • Krug RM, Aramini JM.   Trends Pharmacol Sci. 2009 May 8

• Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
  • Bauer K, Richter M, Wutzler P, Schmidtke M.  Antiviral Res. 2009 Apr;82(1):34-41
• How do adamantane drugs block M2?  See review by Michael Clarkson

Emergence of drug resistant flu: from AS posted in blog comments:

• I study Flu infection in immune compromised hosts. This past flu season there were many persistent flu infections in transplant patients. These patients are being treated with immunospupressive drugs at the same time they are being treated with antivirals. This leads to prolonged shedding of the flu virus accompanied by selective pressure for anti-viral resistant strains to emerge. In the coming 09-10 flu season these patients will be especially vulnerable to H1N1 swine flu infection and will become perfect incubators for a resistant strain to emerge. It has already been documented that tamiflu resistant strains emerge under this prolonged selective pressure and can cause hospital outbreaks.
  • J Clin Virol. 2009 Feb;44(2):138-40. Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient.Cohen-Daniel L, Zakay-Rones Z, Resnick IB, Shapira MY, Dorozhko M, Mador N, Greenbaum E, Wolf DG
    This reference talks about emergence of resistant strains in transplant patients
  • JAMA. 2009 Mar 11;301(10):1066-9.Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM.
    This article talks about hospital transmission among transplant patients.